The genomes of cancer cells often contain changes in their chromosomal architecture and such alterations can be critical to tumor formation and growth progression. Understanding the copy number makeup of solid tumors provides valuable insights into tumor biology, evolution, and resistance to therapy. Studying chromosomal abnormalities and genomic instability is therefore key to fully profiling solid tumors and identifying potentially prognostic and predictive biomarkers.
Catch critical copy number changes with OncoScan CNV Assays. The OncoScan CNV Assay and OncoScan CNV Plus Assay (previously known as OncoScan FFPE Assay Kit) enable accurate analysis of copy number changes and allelic imbalances across the entire genome. These OncoScan CNV assays have been shown to perform well with highly degraded DNA, such as that derived from FFPE tumor samples of various ages, and with low amounts of DNA starting material, making the assay a natural choice for clinical cancer research.
Whole-genome copy number analysis is key to clearly identifying biomarkers that are associated with response or resistance to therapy, are known to have prognostic value, or can distinguish between aggressive and nonaggressive disease states. In this white paper, learn how molecular karyotyping analysis by high-resolution microarray complements, and may one day replace, traditional cytogenetic techniques.
The OncoScan CNV assays utilize molecular inversion probe (MIP) technology (Figure 1), proven for identifying copy number alterations, loss of heterozygosity (LOH), copy neutral LOH (cnLOH), and somatic mutations.
Chromosomal Analysis Suite (ChAS) is a simple yet powerful analysis software enabling you to view and summarize genome-wide chromosomal aberration data from OncoScan CNV assays with just a few clicks.
This webinar explores the importance of cytogenetic analysis for solid tumor profiling, specifically in the research of leiomyosarcoma (LMS) and melanoma.
For Research Use Only. Not for use in diagnostic procedures.